AstraZeneca (NYSE:AZN) is ending the development of rheumatoid arthritis pill Fostamatinib...

AstraZeneca (NYSE:AZN) is ending the development of rheumatoid arthritis pill Fostamatinib following mixed results in Phase II and III trials, including in comparison with Abbott's (NYSE:ABT) Humira. AstraZeneca will take a charge of $140M on its Q2 results and return the rights to Fostamatinib to U.S. partner Rigel Pharmaceuticals (NASDAQ:RIGL), whose shares are -6.8%. AstraZeneca's are -0.2%.